세포 동결 시장 : 예측(2026-2031년)

Cell Freezing Market, at a 7.9% CAGR, is expected to grow to USD 477.361 million in 2031 to USD 302.566 million in 2025.

The cell freezing market, encompassing cryopreservation media, equipment, and associated consumables, is a foundational and growing segment within the life sciences and biotechnology industries. Cryopreservation is the process of preserving cells at ultra-low temperatures, typically below -80°C or in liquid nitrogen, to halt all biological activity and ensure long-term viability and functionality. This technology is critical for preserving valuable biological materials, from research cell lines and primary cells to therapeutic cell products. The market's expansion is driven by the advancement of cell-based therapies, the growing infrastructure for biobanking, continuous technological improvements in preservation protocols, and the rising prevalence of chronic diseases that fuel cellular research.

A primary and powerful driver is the accelerating development and commercialization of cell-based therapies. The fields of regenerative medicine, immunotherapy, and stem cell therapy are fundamentally reliant on robust cryopreservation. Therapies such as CAR-T cells, mesenchymal stem cell treatments, and other advanced therapeutic medicinal products (ATMPs) require that living cellular material be stored, transported, and distributed without loss of potency or function. Cell freezing enables the creation of off-the-shelf allogeneic therapies and ensures the reliable supply chain for autologous treatments, making it an indispensable component of the therapeutic development and delivery pipeline.

Concurrently, the market benefits from the expanding scope and scale of biobanking activities worldwide. Biorepositories for academic research, pharmaceutical R&D, clinical trials, and population health studies all depend on high-integrity, long-term cell storage. The preservation of patient-derived cells, genetically engineered lines, and disease models is essential for biomedical discovery. Institutional, government, and commercial investments in biobanking infrastructure directly translate into sustained demand for high-quality cryopreservation media, specialized storage containers, and reliable cryogenic storage systems.

Technological advancements in cryoprotective agents (CPAs) and freezing methodologies are critical enablers of market growth and application expansion. Research focuses on improving post-thaw cell viability, recovery, and functionality by developing less toxic, serum-free, and sometimes DMSO-free cryopreservation media. Innovations also include controlled-rate freezing equipment that optimizes the cooling curve to minimize ice crystal formation and cellular damage. The development of standardized, GMP-grade freezing protocols is particularly important for clinical and therapeutic applications, where consistency and regulatory compliance are paramount.

The rising global burden of chronic and degenerative diseases acts as an indirect yet significant market driver. Research into conditions such as cancer, cardiovascular disease, neurodegenerative disorders, and diabetes increasingly utilizes cellular models, patient-derived samples, and cell-based screening platforms. This research intensity generates substantial volumes of valuable cellular material that must be preserved for longitudinal studies, replication of experiments, and future use, thereby fueling demand for reliable cryopreservation solutions across academic and industrial laboratories.

Governmental and institutional support for life sciences research further stimulates the market. Public funding initiatives for stem cell research, regenerative medicine, and personalized medicine often include provisions for supporting core facilities, which encompass biobanking and cryopreservation capabilities. This funding environment encourages the adoption of advanced freezing technologies and supports the operational costs of long-term cell storage.

Geographically, North America maintains a leading position, driven by a concentration of biotechnology and pharmaceutical companies, leading academic research institutions, a mature ecosystem for cell therapy development, and significant investment in life sciences R&D. The region's early adoption of new technologies and stringent focus on quality standards for clinical-grade materials reinforces its role as the largest market for sophisticated cell freezing products and services.

Despite strong growth drivers, the market faces specific technical and operational challenges. The toxicity of traditional cryoprotectants like DMSO, though effective, remains a concern for some sensitive cell types and clinical applications, driving the need for improved formulations. Furthermore, cryopreservation is a technically demanding process; successful outcomes depend on precise protocol execution, requiring trained personnel and standardized workflows. Inconsistencies in freezing or thawing can lead to variable cell recovery and compromised experimental or therapeutic results, highlighting the need for robust training and standardized products.

The competitive landscape includes life science reagent suppliers, specialized cryopreservation media companies, and manufacturers of cryogenic storage equipment. Differentiation is based on product performance (post-thaw viability), formulation innovation (e.g., animal-component-free, ready-to-use media), scalability, regulatory support (GMP documentation), and the provision of comprehensive solutions that include media, protocols, and sometimes equipment.

In conclusion, the cell freezing market is evolving from a basic laboratory technique to a critical, industrialized process underpinning the future of medicine and discovery. Its growth is inextricably linked to the progress of cell therapy and the expanding value of biological samples in research. Future development will be shaped by the continued innovation of next-generation cryoprotectants, the integration of automation and closed-system processing to enhance reproducibility, and the establishment of global standards for the cryopreservation of therapeutic cells. As the bioeconomy expands, the ability to reliably "pause" and restart living cells will remain a cornerstone capability, ensuring the market's central and growing role in the life sciences value chain.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Cell Freezing Market Segmentation

• By Media Type
• Glycerol
• Dimethyl Sulfoxide (DMSO)
• By Application
• Stem Cells
• Mammalian Cells
• Others
• By End-User
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CELL FREEZING MARKET BY MEDIA TYPE

• 5.1. Introduction
• 5.2. Glycerol
• 5.3. Dimethyl Sulfoxide (DMSO)

6. CELL FREEZING MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Stem Cells
• 6.3. Mammalian Cells
• 6.4. Others

7. CELL FREEZING MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Academic & Research Institutes
• 7.4. Others

8. CELL FREEZING MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Merch KgaA
• 10.2. Sartorius
• 10.3. Amsbio (Europa Biosite)
• 10.4. Cell Biologics, Inc.
• 10.5. Avantor, Inc.
• 10.6. NIPPON Genetics EUROPE
• 10.7. Thermo Fisher Scientific Inc.
• 10.8. BioLife Solutions Inc.
• 10.9. STEMCELL Technologies Inc.
• 10.10. Takara Bio Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations